Difference between revisions of "Vinorelbine (Navelbine)"
m (→References) |
m (→References) |
||
Line 29: | Line 29: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
+ | [[Category:Intravenous chemotherapy]] | ||
[[Category:Vesicant chemotherapy]] | [[Category:Vesicant chemotherapy]] | ||
Revision as of 18:40, 17 April 2017
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease for which it is used
- Aggressive Non-Hodgkin lymphoma
- Breast cancer
- Cervical cancer
- Hodgkin lymphoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Sarcoma
- Small cell lung cancer
Patient drug information
- Vinorelbine (Navelbine) patient drug information (Chemocare)[3]
- Vinorelbine (Navelbine) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1994: Initial FDA approval
References
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Vesicant chemotherapy
- Microtubule inhibitors
- Vinca alkaloids
- Aggressive Non-Hodgkin lymphoma medications
- Breast cancer medications
- Cervical cancer medications
- Hodgkin lymphoma medications
- Mesothelioma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1994
- WHO Essential Cancer Medicine